EoE treatment showdown: which drug fights scarring better?
NCT ID NCT07358234
First seen Jan 25, 2026 · Last updated May 13, 2026 · Updated 17 times
Summary
This study compares two treatments for eosinophilic esophagitis (EoE): swallowed budesonide (Eohilia) and injected dupilumab (Dupixent). The goal is to see which one better improves esophageal diameter and reduces scarring after 12 weeks. About 60 adults with active EoE will participate at Mayo Clinic locations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EOSINOPHILIC ESOPHAGITIS (EOE) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic
Scottsdale, Arizona, 85259, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.